Novanta Inc (NOVT)
Official siteTECHNOLOGY • SCIENTIFIC & TECHNICAL INSTRUMENTS • NASDAQ
Market Cap: $4.50B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novanta Inc (NOVT) Earnings: Report Dates and Results
Novanta (NOVT) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Novanta reported EPS of $1.05, above the $0.97 estimate. It beat the EPS estimate in each of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NOVT has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 7.7% above the $0.91 reported for the quarter ended Dec 31, 2025.
NOVT Earnings Call
The latest NOVT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, NOVT beat 37 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $305.01M, up 23.1% from $247.84M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.05 | $0.97 | $0.96 - $0.97 | +8.25% | Beat | +20.7% | 3 | 2 up, 0 down | Nov 9, 2026 | $305.01M |
| Jun 30, 2026 | $0.89 | $0.83 | $0.82 - $0.84 | +7.23% | Beat | +17.1% | 3 | 1 up, 2 down | Aug 5, 2026 | $265.81M |
| Mar 31, 2026 | $0.81 | $0.78 | $0.76 - $0.79 | +3.85% | Beat | +9.5% | 3 | 0 up, 2 down | May 11, 2026 | $257.71M |
| Dec 31, 2025 | $0.91 | $0.88 | $0.87 - $0.89 | +3.41% | Beat | +19.7% | 3 | 0 up, 1 down | Feb 23, 2026 | $258.35M |
| Sep 30, 2025 | $0.87 | $0.82 | $0.81 - $0.83 | +6.10% | Beat | +2.4% | 3 | 0 up, 1 down | Nov 3, 2025 | $247.84M |
| Jun 30, 2025 | $0.76 | $0.73 | $0.73 - $0.74 | +4.11% | Beat | +4.1% | 3 | 0 up, 2 down | Aug 5, 2025 | $241.05M |
| Mar 31, 2025 | $0.74 | $0.67 | $0.66 - $0.68 | +10.45% | Beat | 0.0% | 3 | 0 up, 3 down | May 6, 2025 | $233.37M |
| Dec 31, 2024 | $0.76 | $0.71 | $0.71 - $0.72 | +6.55% | Beat | +20.6% | 3 | 0 up, 2 down | Feb 25, 2025 | $238.06M |
| Sep 30, 2024 | $0.85 | $0.85 | $0.85 - $0.86 | 0.00% | In line | 0.0% | 3 | 0 up, 0 down | Nov 5, 2024 | $244.41M |
| Jun 30, 2024 | $0.73 | $0.69 | $0.69 - $0.70 | +5.80% | Beat | -8.8% | 3 | 0 up, 0 down | Aug 6, 2024 | $235.86M |
| Mar 31, 2024 | $0.74 | $0.58 | $0.57 - $0.58 | +27.59% | Beat | 0.0% | 3 | 0 up, 0 down | May 7, 2024 | $230.92M |
| Dec 31, 2023 | $0.63 | $0.63 | $0.62 - $0.63 | 0.00% | In line | -16.0% | 3 | 0 up, 0 down | Feb 28, 2024 | $211.57M |
| Sep 30, 2023 | $0.85 | $0.74 | $0.74 - $0.75 | +14.86% | Beat | +4.9% | 3 | 0 up, 0 down | Nov 7, 2023 | $221.50M |
| Jun 30, 2023 | $0.80 | $0.73 | $0.72 - $0.74 | +9.59% | Beat | +2.6% | 3 | 0 up, 0 down | Aug 8, 2023 | $229.46M |
| Mar 31, 2023 | $0.74 | $0.64 | $0.64 - $0.65 | +15.63% | Beat | +1.4% | 3 | 0 up, 0 down | May 9, 2023 | $219.13M |
| Dec 31, 2022 | $0.75 | $0.72 | $0.69 - $0.74 | +4.17% | Beat | +11.9% | 3 | 0 up, 0 down | Mar 1, 2023 | $218.37M |
| Sep 30, 2022 | $0.81 | $0.74 | $0.73 - $0.75 | +9.46% | Beat | +8.0% | 4 | 0 up, 0 down | Nov 8, 2022 | $222.96M |
| Jun 30, 2022 | $0.78 | $0.72 | $0.72 - $0.72 | +8.33% | Beat | +25.8% | 4 | 0 up, 0 down | Aug 9, 2022 | $215.36M |
| Mar 31, 2022 | $0.73 | $0.63 | $0.62 - $0.64 | +15.87% | Beat | +25.9% | 4 | 0 up, 0 down | May 10, 2022 | $204.22M |
| Dec 31, 2021 | $0.67 | $0.64 | $0.63 - $0.65 | +4.69% | Beat | +26.4% | 4 | 0 up, 0 down | Mar 1, 2022 | $198.96M |
| Sep 30, 2021 | $0.75 | $0.60 | $0.59 - $0.61 | +25.00% | Beat | +78.6% | 4 | N/A | Nov 9, 2021 | $177.73M |
| Jun 30, 2021 | $0.62 | $0.51 | $0.50 - $0.52 | +21.57% | Beat | +29.2% | 4 | N/A | Aug 10, 2021 | $167.52M |
| Mar 31, 2021 | $0.58 | $0.39 | $0.38 - $0.41 | +48.72% | Beat | +13.7% | 4 | N/A | May 11, 2021 | $162.58M |
| Dec 31, 2020 | $0.53 | $0.44 | $0.42 - $0.45 | +20.45% | Beat | -3.6% | 4 | N/A | Mar 1, 2021 | $147.50M |
| Sep 30, 2020 | $0.42 | $0.39 | $0.38 - $0.42 | +7.69% | Beat | -20.8% | 3 | N/A | Nov 10, 2020 | $142.93M |
| Jun 30, 2020 | $0.48 | $0.23 | $0.20 - $0.28 | +108.70% | Beat | -11.1% | 3 | N/A | Aug 6, 2020 | $144.73M |
| Mar 31, 2020 | $0.51 | $0.32 | $0.25 - $0.39 | +59.38% | Beat | -3.8% | 3 | N/A | May 12, 2020 | $155.47M |
| Dec 31, 2019 | $0.55 | $0.54 | $0.53 - $0.54 | +1.85% | Beat | -1.8% | 3 | N/A | Feb 26, 2020 | $159.70M |
| Sep 30, 2019 | $0.53 | $0.52 | $0.51 - $0.52 | +1.92% | Beat | -13.1% | 3 | N/A | Nov 5, 2019 | $154.07M |
| Jun 30, 2019 | $0.54 | $0.54 | $0.54 - $0.54 | 0.00% | In line | +5.9% | 3 | N/A | Aug 6, 2019 | $155.15M |
| Mar 31, 2019 | $0.53 | $0.48 | $0.48 - $0.49 | +10.42% | Beat | +12.8% | 3 | N/A | May 7, 2019 | $157.19M |
| Dec 31, 2018 | $0.56 | $0.51 | $0.51 - $0.52 | +9.80% | Beat | +27.3% | 3 | N/A | Feb 27, 2019 | $156.18M |
| Sep 30, 2018 | $0.61 | $0.52 | $0.51 - $0.52 | +17.31% | Beat | +35.6% | 3 | N/A | Nov 6, 2018 | $160.79M |
| Jun 30, 2018 | $0.51 | $0.49 | $0.48 - $0.49 | +4.08% | Beat | +24.4% | 3 | N/A | Aug 8, 2018 | $150.40M |
| Mar 31, 2018 | $0.47 | $0.40 | $0.38 - $0.41 | +17.50% | Beat | +51.6% | 3 | N/A | May 8, 2018 | $146.97M |
| Dec 31, 2017 | $0.44 | $0.41 | $0.40 - $0.41 | +7.32% | Beat | +25.7% | 3 | N/A | Feb 28, 2018 | $146.92M |
| Sep 30, 2017 | $0.45 | $0.34 | $0.34 - $0.34 | +32.35% | Beat | +55.2% | 1 | N/A | Nov 1, 2017 | $146.30M |
| Jun 30, 2017 | $0.41 | $0.33 | $0.33 - $0.33 | +24.24% | Beat | +51.9% | 1 | N/A | Aug 3, 2017 | $119.10M |
| Mar 31, 2017 | $0.31 | $0.24 | N/A | +29.17% | Beat | +72.2% | N/A | N/A | May 8, 2017 | $108.97M |
| Dec 31, 2016 | $0.35 | $0.28 | N/A | +25.00% | Beat | +20.7% | N/A | N/A | Mar 6, 2017 | $98.88M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $3.28, up 6.5% from the year before. It was $1.09 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $3.28 | +6.5% |
| Dec 31, 2024 | $3.08 | +2.0% |
| Dec 31, 2023 | $3.02 | -1.6% |
| Dec 31, 2022 | $3.07 | +17.2% |
| Dec 31, 2021 | $2.62 | +35.1% |
| Dec 31, 2020 | $1.94 | -9.8% |
| Dec 31, 2019 | $2.15 | N/A |
| Dec 31, 2018 | $2.15 | +33.5% |
| Dec 31, 2017 | $1.61 | +47.7% |
| Dec 31, 2016 | $1.09 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,700 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,743 | 8 | |
| 2026Q2 | Jun 30, 2026 | 6,150 | 9 | |
| 2026Q1 | Mar 31, 2026 | 7,299 | 7 | |
| 2025Q4 | Dec 31, 2025 | 8,272 | 7 | |
| 2025Q3 | Sep 30, 2025 | 6,148 | 7 | |
| 2025Q2 | Jun 30, 2025 | 7,409 | 7 | |
| 2025Q1 | Mar 31, 2025 | 7,189 | 7 | |
| 2024Q4 | Dec 31, 2024 | 8,319 | 7 |
2026Q3 Earnings Call
Opening remarks
Marcella Meditz Corporate Finance Leader Thank you very much. Good morning, and welcome to Novanta's Third Quarter 2026 Earnings Conference Call. This is Marcella Meditz, Corporate Finance Leader for Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra; our Chief Financial Officer, Robert Buckley; and our Co-Chief Operating Officers, Chuck Ravetto and John Lesica. If you have not received a copy of our earnings press release issued last night, you may obtain it from the Investor Relations section of our website at www.novanta.com. Please note, this call is being webcast live and will be archived on our website shortly after the call. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued last night and also those in our SEC filings. We may make some comments today, both in our prepared remarks and in our responses to questions, that may include forward-looking statements. These involve inherent assumptions with known and unknown risks and other factors that could cause our future results to differ materially from our current expectations. Any forward-looking statements made today represent our views only as of this time. We disclaim any obligation to update forward-looking statements in the future, even if our estimates change. You should not rely on any of these forward-looking statements as representing our views as of any time after this call. During this call, we will be referring to certain non-GAAP financial measures. A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available as an attachment to our earnings press release. To the extent that we use non-GAAP financial measures during this call that are not reconciled to GAAP measures in the earnings press release, we will provide reconciliations promptly on the Investor Relations section of our website after this call. I am now pleased to introduce the Chair and Chief Executive Officer of Novanta, Matthijs Glastra.
Matthijs Glastra Chair and CEO Thank you, Marcella. Good morning, everybody, and thanks for joining our call. The third quarter was a milestone quarter for Novanta. We closed the largest acquisition in our history, Riverpoint Medical, and at the same time delivered results ahead of expectations on revenue, adjusted EBITDA, and adjusted EPS. Revenue grew 23% on a reported basis to $305 million, with organic growth of nearly 10%, our strongest organic growth in more than three years. Adjusted EBITDA grew 38% to $80 million, or a 26% EBITDA margin, the highest in Novanta's history, and an expansion of 290 basis points year over year. Adjusted EPS grew 21% to $1.05.
Frequently Asked Questions About NOVT
When is Novanta's next earnings date?
Novanta's next earnings report is expected for Feb 22, 2027.
Did NOVT beat earnings estimates last quarter?
Yes. Novanta reported EPS of $1.05 for the quarter ended Sep 30, 2026, above the $0.97 estimate, a 8.25% surprise.
What EPS do analysts expect from NOVT next quarter?
The consensus EPS estimate for Novanta for the quarter ending Dec 31, 2026 is $0.98 from 5 analysts, with estimates from $0.91 to $1.07.
How often does NOVT beat earnings estimates?
Novanta beat the EPS estimate in each of the last 8 quarters, with an average surprise of +6.24%.
NOVT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors